An Open-label, Single-Sequence Study to Evaluate the Effects of Diltiazem, a Moderate CYP3A4/A5 Inhibitor, on the Pharmacokinetics and Pharmacodynamics of E5555 and Its Metabolites in Healthy Subjects.

Trial Profile

An Open-label, Single-Sequence Study to Evaluate the Effects of Diltiazem, a Moderate CYP3A4/A5 Inhibitor, on the Pharmacokinetics and Pharmacodynamics of E5555 and Its Metabolites in Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Sep 2014

At a glance

  • Drugs Atopaxar (Primary) ; Diltiazem
  • Indications Acute coronary syndromes; Angina pectoris; Coronary disorders; Hypertension
  • Focus Pharmacodynamics; Pharmacokinetics
  • Sponsors Eisai Inc
  • Most Recent Events

    • 14 Jan 2011 Actual end date (Dec 2010 ) added as reported by ClinicalTrials.gov.
    • 14 Jan 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 20 Dec 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top